These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7241091)

  • 21. Magnitude and Functional Profile of the Human CD4
    Varnaitė R; Blom K; Lampen MH; Vene S; Thunberg S; Lindquist L; Ljunggren HG; Rombo L; Askling HH; Gredmark-Russ S
    J Immunol; 2020 Feb; 204(4):914-922. PubMed ID: 31924650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children.
    Eder G; Kollaritsch H
    Vaccine; 2003 Sep; 21(25-26):3575-83. PubMed ID: 12922085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination against tick-borne encephalitis--distant evaluation.
    Bobrowska E; Grzeszczuk A; Prokopowicz D
    Rocz Akad Med Bialymst; 1996; 41(1):44-50. PubMed ID: 8673804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme.
    Loew-Baselli A; Poellabauer EM; Pavlova BG; Fritsch S; Firth C; Petermann R; Barrett PN; Ehrlich HJ
    Vaccine; 2011 Oct; 29(43):7307-19. PubMed ID: 21843576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Field effectiveness of vaccination against tick-borne encephalitis.
    Heinz FX; Holzmann H; Essl A; Kundi M
    Vaccine; 2007 Oct; 25(43):7559-67. PubMed ID: 17869389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Reactogenicity and immunological effectiveness of a concentrated, purified vaccine against tick-borne encephalitis].
    Vorob'eva MS; El'bert LB; Grachev VP; Lelikov VL; Pervikov IuV
    Vopr Virusol; 1983; 28(5):622-6. PubMed ID: 6659477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.
    Beran J; Lattanzi M; Xie F; Moraschini L; Galgani I
    Vaccine; 2019 Jul; 37(32):4623-4629. PubMed ID: 29397225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation.
    Heinz FX; Kunz C; Fauma H
    J Med Virol; 1980; 6(3):213-21. PubMed ID: 7014784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of the efficiency of tick-borne encephalitis vaccination in the population in the natural foci of Austria].
    Heinz F; Holtzmann H; Essl A; Kundt M
    Vopr Virusol; 2008; 53(2):19-27. PubMed ID: 18450105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
    Zent O; Schwarz TF; Plentz A; Banzhoff A; Jilg W
    Int J Med Microbiol; 2004 Apr; 293 Suppl 37():134-8. PubMed ID: 15146995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events.
    von Hedenström M; Heberle U; Theobald K
    Vaccine; 1995; 13(8):759-62. PubMed ID: 7483792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children.
    Wittermann C; Petri E; Zent O
    Vaccine; 2009 Mar; 27(10):1585-8. PubMed ID: 19162115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tick-borne encephalitis in China: A review of epidemiology and vaccines.
    Xing Y; Schmitt HJ; Arguedas A; Yang J
    Vaccine; 2017 Mar; 35(9):1227-1237. PubMed ID: 28153343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dynamics of antibody formation after vaccination against tick-borne encephalitis].
    Pazdiora P; Januska J
    Epidemiol Mikrobiol Imunol; 2004 Feb; 53(1):17-21. PubMed ID: 15052830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice.
    Ershova AS; Gra OA; Lyaschuk AM; Grunina TM; Tkachuk AP; Bartov MS; Savina DM; Sergienko OV; Galushkina ZM; Gudov VP; Kozlovskaya LI; Kholodilov IS; Gmyl LV; Karganova GG; Lunin VG; Karyagina AS; Gintsburg AL
    BMC Infect Dis; 2016 Oct; 16(1):544. PubMed ID: 27717318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunological status of people inoculated with various types of inactivated vaccine against tick-borne encephalitis].
    Pervikov IuV; El'bert LB; Krutianskaia GL; Belotskiĭ SM; Krasil'nikov IV
    Vopr Virusol; 1982; 27(6):696-701. PubMed ID: 7157778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia.
    Craig SC; Pittman PR; Lewis TE; Rossi CA; Henchal EA; Kuschner RA; Martinez C; Kohlhase KF; Cuthie JC; Welch GE; Sanchez JL
    Am J Trop Med Hyg; 1999 Dec; 61(6):874-8. PubMed ID: 10674662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules.
    Wittermann C; Schöndorf I; Gniel D
    Vaccine; 2009 Mar; 27(10):1661-6. PubMed ID: 18940221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Donor immunization with an inactivated concentrated purified vaccine against tick-borne encephalitis to obtain immune blood preparations].
    El'bert LB; Pervikov IuV; Grachev VP; Rusanov VM; Krokhina MA
    Vopr Virusol; 1984; 29(1):56-9. PubMed ID: 6608828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccination against tick-borne encephalitis using the Soviet liquid inactivated vaccine].
    Plesník V; Januska J; Matuska J
    Cesk Epidemiol Mikrobiol Imunol; 1984 Nov; 33(6):338-45. PubMed ID: 6239701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.